Senate Passes Resolution to Spare NIH From Major Cuts in Funding

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--The $1 billion cut that the National Institutes of Health (NIH) had anticipated has been shelved for the time being. The Senate voted 85 to 14 on a resolution by Sen. Mark Hatfield (R-OR) to spare NIH from the need to make serious cuts in a wide variety of programs and initiatives.

WASHINGTON--The $1 billion cut that the National Institutes ofHealth (NIH) had anticipated has been shelved for the time being.The Senate voted 85 to 14 on a resolution by Sen. Mark Hatfield(R-OR) to spare NIH from the need to make serious cuts in a widevariety of programs and initiatives.

In a similar move, the House of Representatives passed a resolutionthat would cut the NIH budget by only 5% and keep the budget frozenthrough the year 2002.

Sen. Arlen Specter (R-PA), chairman of the Labor, HHS, and EducationAppropriations Subcommittee, devised a bipartisan strategy toprevent drastic budget slashing for NIH. He requested that NIHDirector Harold Varmus and several institute directors providethe subcommittee with strong written statements to describe NIHgoals.

NCI Acting Director Edward Sondik said that the proposed cutswould cause great harm to the institute, especially in terms offunding new grants and continuing work on the Human Genome Project.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content